Overview

Extension to a Study on the Efficacy and Safety of Vildagliptin in Combination With Pioglitazone in Patients With Type 2 Diabetes

Status:
Completed
Trial end date:
2006-07-01
Target enrollment:
0
Participant gender:
All
Summary
Many people with type 2 diabetes cannot maintain target blood glucose levels when taking a single oral drug. This is a 28-week extension to a study to assess the safety and effectiveness of vildagliptin, an unapproved drug, in lowering overall blood glucose levels when added to pioglitazone in people with type 2 diabetes not at target blood glucose levels on pioglitazone or rosiglitazone alone. The purpose of the extension study is to gather data on the long-term safety and effectiveness of vildagliptin in people with type 2 diabetes.
Phase:
Phase 3
Details
Lead Sponsor:
Novartis
Treatments:
Pioglitazone
Vildagliptin
Criteria
Inclusion Criteria:

- Only patients successfully completing study CLAF237A2304 are eligible

- Written informed consent

- Ability to comply with all study requirements

Exclusion Criteria:

- Premature discontinuation from study CLAF237A2304

- Other protocol-defined exclusion criteria may apply